Choosing the backbone before the insert: why mammalian expression vectors differ in promoter strength, selection marker and whether they integrate, and why the choice constrains everything downstream, what a promoter suited to transient work does badly in a stable line, where an inducible system earns its extra construct, how a reporter gene assay reads out the vector rather than the protein, what plasmid design software helps with and where reading the actual sequence is faster, and what has to be verified about a backbone before it is used across a programme
A vector backbone carries decisions that outlast the insert: how strongly the gene is transcribed, how cells carrying it are selected, whether it persists and what tags it adds. Those decisions are made once and inherited by every construct built on it, which is why the backbone deserves more attention than it usually gets.
- the biosafety manual that decides handling for biological material
- BMBL
- good laboratory practice for nonclinical studies, 21 CFR
- Part 58
- the labelling clause behind research use only on a reagent
- 809.10(c)
The figures in this panel are regulation and standard identifiers, named from the documents themselves and linked below. They are not prices: BioBricks publishes verified prices for synthesis services only, and does not imply a price index it has not measured.
- 4 vendor service pages verifiedevery figure matched verbatim to the vendor's page
- Quoted and dated, never estimatedlast verification pass 2026-08-24
- 1 service classes coveredeach with measured search demand behind it
Choosing and verifying a backbone
- Match promoter strength to the experiment. A very strong constitutive promoter suits transient overexpression and can be silenced or toxic in a stable line. Weaker or endogenous-like promoters suit long term expression.
- Choose the selection marker for the host. Resistance markers differ in how quickly they kill, in background survival and in whether the host already carries resistance. Kill curves on your cells are what set the concentration.
- Decide integration deliberately. Episomal vectors are lost with division; integrating vectors persist and insert somewhere. Transposon and site specific systems give integration with more control than random insertion.
- Add an inducible system only where timing matters. Induction control costs an extra construct and adds leakiness to manage. It earns that where the product is toxic or where onset timing is the question.
- Verify the backbone once, properly. Whole plasmid sequencing of the empty backbone, kept as a reference. Every construct built on it then inherits verified sequence and only the insert has to be checked.
- Record the map and the licence terms. Backbones frequently carry commercial terms that follow every construct made from them. Establish them before a programme standardises on one.
The backbone is inherited
Every construct built on a backbone carries its promoter, marker, tags and licence terms. Standardising on a poorly chosen one propagates the problem across a laboratory for years.
Choose it deliberately, sequence it once and document the map where everyone building constructs can see it.
Selection has to be calibrated
Selection concentration depends on the cell line, the confluence and the marker, and using a concentration from another laboratory leaves untransfected cells alive or kills everything.
Run a kill curve per cell line, record it, and repeat it when the line or the serum lot changes.
Common questions
- Why is my strong promoter silenced?
- Very strong viral promoters are frequently silenced over time in stable lines, particularly in primary and stem cells. A weaker or more endogenous promoter usually gives lower but durable expression.
- Episomal or integrating?
- Episomal for short transient work with no insertion. Integrating for durable expression, accepting an insertion site and its effects. Transposon or site specific systems sit between them with more control.
- Do I need to sequence every construct?
- Sequence the backbone once and keep it as a reference; then whole plasmid sequencing of each new construct is cheap and catches rearrangements a junction read misses.
Get a shortlist for your project
Browse by service class
Sources
Cite or embed this figure
The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.
Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/mammalian-expression-vectors/.